Yasser Medhat Kamel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yasser Medhat Kamel has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Deema Hussam Alsoub
Hamad Medical Corporation, Doha, Qatar
2 shared publications - Kamran Mushtaq
Hamad Medical Corporation, Doha, Qatar
2 shared publications - Muhammad Umair Khan
Department of Gastroenterology Hamad Medical Corporation Doha Qatar
2 shared publications Saad AlKaabi
Department of Gastroenterology and Hepatology, Hamad Medical Corporation
2 shared publicationsAliaa Mohamed Amer
Moutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar
1 shared publicationEman Hassan Satti Elsayed
Moutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Hepatology
- Vol. 2025 (1)
Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report
Primary biliary cholangitis is a progressive disease with complications such as liver cirrhosis and hepatocellular carcinoma, and the treatment goal is to delay its progression. One of the markers for treatment response is alkaline phosphatase levels. Baricitinib has been used in one randomized controlled trial involving two patients to improve outcomes in unresponsive primary biliary cholangitis. We present a case of primary biliary cholangitis who had incomplete response to ursodeoxycholic acid, obeticholic acid, and fenofibrate but showed complete response to baricitinib in terms of sustained normalized alkaline phosphatase levels.
- 1 January 2025
- Published by Wiley in Case Reports in Hepatology
- Vol. 2025 (1)
Open AccessPrimary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to Baricitinib: A Case Report
Primary biliary cholangitis is a progressive disease with complications such as liver cirrhosis and hepatocellular carcinoma, and the treatment goal is to delay its progression. One of the markers for treatment response is alkaline phosphatase levels. Baricitinib has been used in one randomized controlled trial involving two patients to improve outcomes in unresponsive primary biliary cholangitis. We present a case of primary biliary cholangitis who had incomplete response to ursodeoxycholic acid, obeticholic acid, and fenofibrate but showed complete response to baricitinib in terms of sustained normalized alkaline phosphatase levels.
P78 The discrepancy between GGT and alkaline phosphatase in COVID-19 patients: cholestasis or disease severity?
Introduction COVID-19 patients with abnormal liver tests, especially ALT and AST, are at higher risk of progressing to severe disease. There is a discrepancy between gamma glutamyl transferase (GGT) and alkaline phosphatase elevation (ALP) in COVID-19 patients. We hypothesized that elevated GGT at admission in COVID-19 patients is independently associated with disease severity and adverse outcomes. Methods We studied 232 patients with confirmed symptomatic COVID-19 who were consecutively hospitalized in the first half of March 2021 in our hospital in Qatar. We categorized them into three groups; borderline if GGT was normal or less than twice the upper limit of normal (ULN), mild if elevated 2-5 times, and moderate if more than five times the ULN. The primary outcome was mortality, and secondary outcomes were disease severity on presentation and intensive Care Unit (ICU) admission. The Medical Research Centre of Hamad Medical Corporation approved the study. Results Patients with moderate GGT elevation were not different in age, BMI, gender distribution, Charlson comorbid index, transaminase levels, albumin, and bilirubin levels but had elevated ferritin and LDH levels. For ALP levels, 75% of the patients had normal levels, 18% had borderline elevation (less than twice the ULN), and the remaining had mild elevation (2x -5x). In univariate analysis, COVID-19 patients with moderate GGT elevation had higher mortality (p = 0.006) and more severe disease at presentation (p=0.003), but no statically increased risk of ICU admission and requirement of mechanical ventilation. In multivariate regression analysis, patients with moderate GGT elevation remained at increased risk of mortality odds ratio (OR) 3.09 (C.I. 1.1-9.67 p = 0.04) and severe disease at presentation OR 1.57 (C.I.1.2 – 2.65 p=0.048). Conclusions In COVID-19 patients, the moderate elevation of GGT at presentation is an independent predictor of disease severity and increased mortality. Elevated GGT levels are a marker of disease severity rather than cholestasis in COVID-19 patients.
P78 The discrepancy between GGT and alkaline phosphatase in COVID-19 patients: cholestasis or disease severity?
Introduction COVID-19 patients with abnormal liver tests, especially ALT and AST, are at higher risk of progressing to severe disease. There is a discrepancy between gamma glutamyl transferase (GGT) and alkaline phosphatase elevation (ALP) in COVID-19 patients. We hypothesized that elevated GGT at admission in COVID-19 patients is independently associated with disease severity and adverse outcomes. Methods We studied 232 patients with confirmed symptomatic COVID-19 who were consecutively hospitalized in the first half of March 2021 in our hospital in Qatar. We categorized them into three groups; borderline if GGT was normal or less than twice the upper limit of normal (ULN), mild if elevated 2-5 times, and moderate if more than five times the ULN. The primary outcome was mortality, and secondary outcomes were disease severity on presentation and intensive Care Unit (ICU) admission. The Medical Research Centre of Hamad Medical Corporation approved the study. Results Patients with moderate GGT elevation were not different in age, BMI, gender distribution, Charlson comorbid index, transaminase levels, albumin, and bilirubin levels but had elevated ferritin and LDH levels. For ALP levels, 75% of the patients had normal levels, 18% had borderline elevation (less than twice the ULN), and the remaining had mild elevation (2x -5x). In univariate analysis, COVID-19 patients with moderate GGT elevation had higher mortality (p = 0.006) and more severe disease at presentation (p=0.003), but no statically increased risk of ICU admission and requirement of mechanical ventilation. In multivariate regression analysis, patients with moderate GGT elevation remained at increased risk of mortality odds ratio (OR) 3.09 (C.I. 1.1-9.67 p = 0.04) and severe disease at presentation OR 1.57 (C.I.1.2 – 2.65 p=0.048). Conclusions In COVID-19 patients, the moderate elevation of GGT at presentation is an independent predictor of disease severity and increased mortality. Elevated GGT levels are a marker of disease severity rather than cholestasis in COVID-19 patients.
- 1 February 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (2) , 482-484
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues
- 1 February 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 74 (2) , 482-484
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (46) , 13132-9
Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection
AIM: To assess the diagnostic accuracy, of aminotransferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection. METHODS: This retrospective study included medical records of three hundred and eighty three Egyptian men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present. RESULTS: Median age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage. CONCLUSION: The study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (46) , 13132-9
Open AccessAspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection
AIM: To assess the diagnostic accuracy, of aminotransferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection. METHODS: This retrospective study included medical records of three hundred and eighty three Egyptian men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present. RESULTS: Median age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage. CONCLUSION: The study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.